Cardio Diagnostics Holdings (CDIO) Depreciation & Amortization (CF) (2023 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Depreciation & Amortization (CF) of $44240.0 for Q1 2026, little changed sequentially from $44220.0 in Q4 2025, and up 17.48% YoY from $37656.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $44240.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 17.48% year-over-year to $44240.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102600.0 (up 21.15% YoY) and the FY2025 annual result came in at $160063.0, up 40.68% from the prior year.
- Depreciation & Amortization (CF) was little changed at $44240.0 in Q1 2026 per CDIO's latest filing, from $44220.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $44240.0 in Q1 2026 and troughed at $1377.0 in Q3 2023.
- A 4-year average of $17696.8 and a median of $5655.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) surged 1451.43% in 2024, then gained 17.48% in 2026.
- Over 4 years, Depreciation & Amortization (CF) stood at $2413.0 in 2023, then soared by 1451.43% to $37436.0 in 2024, then advanced by 18.12% to $44220.0 in 2025, then advanced by 0.05% to $44240.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $44240.0, $44220.0, and $5655.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44,283.00 |
| Jun 30, 2026 | 44,283.00 |
| Mar 31, 2026 | 44,240.00 |
| Mar 31, 2026 | 44,240.00 |
| Dec 31, 2025 | 44,220.00 |
| Dec 31, 2025 | 44,220.00 |
| Sep 30, 2025 | 5,655.00 |
| Sep 30, 2025 | 5,655.00 |
| Jun 30, 2025 | 8,485.00 |
| Jun 30, 2025 | 8,485.00 |
| Mar 31, 2025 | 37,656.00 |
| Mar 31, 2025 | 37,656.00 |
| Dec 31, 2024 | 37,436.00 |
| Dec 31, 2024 | 37,436.00 |
| Sep 30, 2024 | 4,802.00 |
| Sep 30, 2024 | 4,802.00 |
| Jun 30, 2024 | 4,794.00 |
| Jun 30, 2024 | 4,794.00 |
| Mar 31, 2024 | 3,587.00 |
| Mar 31, 2024 | 3,587.00 |